类风湿性关节炎:病原和治疗进展
Ying Gao1, Yunkai Zhang2, Xingguang Liu3,4
1Department of Rheumatology Changhai Hospital Naval Medical University Shanghai China.
MedComm
|March 12, 2024
概括
类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,影响全球数百万人. 本综述探讨了RA的发病过程,包括免疫,遗传和代谢因素,并讨论了用于改善治疗结果的新型向疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 遗传学 遗传学 是一个
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,导致持续的突关节炎症和组织破坏.
- 影响0.2-1%的全球人口,RA导致严重的残疾和经济损失.
- 目前的治疗方法,包括改变疾病的抗风湿性药物 (DMARDs),缓解率有限,需要更深入的理解和新的治疗方法.
研究的目的:
- 总结一下RA的免疫基础,炎症途径,遗传/表观遗传变化和代谢障碍.
- 审查当前的RA治疗方法,并讨论有前途的向疗法,重点关注表观遗传和代谢调节者.
- 探索精准医学和RA细胞疗法的未来前景.
主要方法:
- 关于RA病变发生和治疗的现有文献的全面审查.
- 对导致RA的免疫学,遗传学,表观遗传学和代谢因素的分析.
- 讨论用于新型治疗策略的临床和临床前数据.
主要成果:
- RA 的发病包括免疫细胞,遗传因素,表观遗传修饰和代谢失调的复杂相互作用.
- 免疫细胞图谱,表观遗传学和免疫代谢的异常是RA的关键特征.
- 新兴的向疗法,包括表观遗传和代谢调节剂,显示出希望.
结论:
- 了解RA病变的进展对于开发创新的治疗方法至关重要.
- 针对性治疗和精准医学方法具有显著的潜力,可以改善RA患者的治疗结果.
- 以细胞疗法和个性化策略为重点的未来研究将加速RA管理的进展.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Genome-wide Association Studies-GWAS
13.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.4K
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Autoimmune Disorders
434
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
434
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


